BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9333137)

  • 1. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Chapurlat RD; Delmas PD; Liens D; Meunier PJ
    J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
    Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
    Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
    Parisi MS; Oliveri B; Mautalen CA
    Bone; 2003 Oct; 33(4):582-8. PubMed ID: 14555262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy in adults with fibrous dysplasia of bone.
    Chapurlat RD
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P114-9. PubMed ID: 17228999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Liens D; Delmas PD; Meunier PJ
    Lancet; 1994 Apr; 343(8903):953-4. PubMed ID: 7909013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate therapy in fibrous dysplasia.
    Lane JM; Khan SN; O'Connor WJ; Nydick M; Hommen JP; Schneider R; Tomin E; Brand J; Curtin J
    Clin Orthop Relat Res; 2001 Jan; (382):6-12. PubMed ID: 11154006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
    Plotkin H; Rauch F; Zeitlin L; Munns C; Travers R; Glorieux FH
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4569-75. PubMed ID: 14557424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Matarazzo P; Lala R; Masi G; Andreo M; Altare F; de Sanctis C
    J Pediatr Endocrinol Metab; 2002; 15 Suppl 3():929-37. PubMed ID: 12199352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates for the treatment of fibrous dysplasia of bone.
    Chapurlat R; Legrand MA
    Bone; 2021 Feb; 143():115784. PubMed ID: 33276154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Gutteridge DH; Retallack RW; Ward LC; Stuckey BG; Stewart GO; Prince RL; Kent GN; Bhagat CI; Price RI; Thompson RI; Nicholson GC
    Bone; 1996 Oct; 19(4):387-94. PubMed ID: 8894145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
    Lala R; Matarazzo P; Bertelloni S; Buzi F; Rigon F; de Sanctis C
    Acta Paediatr; 2000 Feb; 89(2):188-93. PubMed ID: 10709889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
    Pfeilschifter J; Ziegler R
    Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density.
    Weinstein RS
    J Bone Miner Res; 1997 Aug; 12(8):1314-5. PubMed ID: 9258763
    [No Abstract]   [Full Text] [Related]  

  • 16. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.
    Florenzano P; Pan KS; Brown SM; Paul SM; Kushner H; Guthrie LC; de Castro LF; Collins MT; Boyce AM
    J Bone Miner Res; 2019 Apr; 34(4):653-660. PubMed ID: 30645769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.
    Cundy T; Wheadon L; King A
    J Bone Miner Res; 2004 May; 19(5):703-11. PubMed ID: 15068492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrous dysplasia of bone.
    Chapurlat RD; Meunier PJ
    Baillieres Best Pract Res Clin Rheumatol; 2000 Jun; 14(2):385-98. PubMed ID: 10925751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of Paget's disease with bisphosphonate pamidronate (AHPrBP, formerly APD)].
    Scharla SH; Grauer A; Ziegler R
    Klin Wochenschr; 1991 Jan; 69(1):25-30. PubMed ID: 2016845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome.
    Zacharin M; O'Sullivan M
    J Pediatr; 2000 Sep; 137(3):403-9. PubMed ID: 10969268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.